The phase 3 randomized clinical trial involves a clonidine micropellet, which is half the size of a grain of rice and placed in the lower back to combat sciatica pain for up to one year.
Interventional pain company Sollis Therapeutics developed the micropellet as a non-opioid alternative to treat chronic pain caused by sciatica. More than 5 million people in the U.S. suffer from sciatica, which is one of the most common causes of back and leg pain.
“Innovative technologies that act directly at a target location like this micropellet are crucial to reducing the need for systemic medications and opioids for chronic pain,” said neurosurgeon Ali Rezai, MD.
More articles on spine:
Dr. Joshua Rovner among spine surgeons performing robotic surgery: 3 details
Top 10 ‘Spine Review’ articles: Nov. 19-23
What spine surgeons are most thankful for in 2018
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
